MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5152/tjg.2022.21834

Медицинская библиотека · The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey.

Sarıgül Yıldırım Figen, Üser Ülkü, Sarı Nagehan Didem, Kurtaran Behice, Önlen Yusuf, Şenateş Ebubekir, Gündüz Alper, Zerdali Esra, Karsen Hasan, Batırel Ayşe, Karaali Rıdvan, Güner Rahmet, Yamazhan Tansu, Köse Şükran, Erben Nurettin, İnce Nevin, Köksal İftihar, Çuvalcı Öztoprak Nefise, Yörük Gülşen, Kömür Süheyla, Bal Tayibe, Kaya Sibel, Bozkurt İlkay, Günal Özgür, Yıldız İlknur Esen, İnan Dilara, Barut Şener, Namıduru Mustafa, Tosun Selma, Türker Kamuran, Şener Alper, Hızel Kenan, Baykam Nurcan, Duygu Fazilet, Bodur Hürrem, Can Güray, Gül Hanefi Cem, Sağmak Tartar Ayşe, Çelebi Güven, Sünnetçioğlu Mahmut, Karabay Oğuz, Kumbasar Karaosmanoğlu Hayat, Sırmatel Fatma, Tabak Fehmi

Многоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting.

METHODS

We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed.

RESULTS

Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%).

CONCLUSION

Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.

Для цитирования: Sarıgül Yıldırım Figen, Üser Ülkü, Sarı Nagehan Didem, Kurtaran Behice, Önlen Yusuf, Şenateş Ebubekir, Gündüz Alper, Zerdali Esra, Karsen Hasan, Batırel Ayşe, Karaali Rıdvan, Güner Rahmet, Yamazhan Tansu, Köse Şükran, Erben Nurettin, İnce Nevin, Köksal İftihar, Çuvalcı Öztoprak Nefise, Yörük Gülşen, Kömür Süheyla, Bal Tayibe, Kaya Sibel, Bozkurt İlkay, Günal Özgür, Yıldız İlknur Esen, İnan Dilara, Barut Şener, Namıduru Mustafa, Tosun Selma, Türker Kamuran, Şener Alper, Hızel Kenan, Baykam Nurcan, Duygu Fazilet, Bodur Hürrem, Can Güray, Gül Hanefi Cem, Sağmak Tartar Ayşe, Çelebi Güven, Sünnetçioğlu Mahmut, Karabay Oğuz, Kumbasar Karaosmanoğlu Hayat, Sırmatel Fatma, Tabak Fehmi. In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey.. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2022. DOI: 10.5152/tjg.2022.21834.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.